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Background
Autoimmune hepatitis (AIH) is a progressive inflamma-
tory fribrosing disease of the liver of unknown etiology,
which in its normal progress leads to cirrhosis. It is
characterized by the increase in aminotranferases and
hypergammaglobulinemia, and the presence of non-
organ and specific liver autoantibodies in serum, which
allow for its classification. Two subtypes are differen-
tiated: Type I AIH with anti-smooth muscle antibodies
(SMA) and/or antinuclear antibodies (ANA); and Type
II AIH with antimichondrial antibodies (LKM).
AIH can be associated with other autoimmune ill-
nesses such as thyroiditis, Type I diabetes, thrombocyto-
penia, hemolytic anaemia and ulcerative colitis.
Likewise, the association to connective tissue diseases
(CTD) has been communicated, such as Systemic Lupus
Erythematosus, Sjögren’s Syndrome, Undifferentiated
Connective Tissue Disease, Mixed Connective Tissue
Disease, Localized Sclerodermia and Juvenile Idiopathic
Arthritis.
Aim
We aim to research defined or probable clinical and
laboratory manifestations of CTD in patients with AIH
diagnosis in pediatric age.
Methods
20 records of patients with AIH diagnosis under care in
the Hepatology Unit and Rheumatology Unit were ana-
lyzed retrospectively since 1995 until May 2008.
Results
In the group of 20 patients, 6 were male (30%) and 14
were female (70%). Their average AIH diagnosis age was
9.6 yrs (Min 1.4 yrs-Max 15.2 yrs). Type I AIH diagnosis
occurred in 18/20 patients (90%), 5 males (27.8%) and
13 females (72.2%), their average diagnosis age being 9.8
yrs (Min 1.4 yrs-Max 15.2 yrs), and Type II AIH diagno-
sis occurred in 2/20 patients (10%), 1 male and 1 female.
Their average AIH diagnosis age was 7.5 yrs (Min 4.2
yrs-Max 10.9 yrs). Average follow-up period of the
patients until the end of the study was 41.4 months in
average.
8/20 patients with defined AIH (40%) showed some
manifestations of CTD in their progress; 6/18 patients
with Type I AIH (33.3%), 2 males and 6 females, and 2/
2 patients with Type II AIH (100%). Most common
manifestations were: arthralgia/arthritis, vasculitis, AHA
with positive Coombs’ Test results, oral ulcers, hypo-
complementemia, leukopenia/lymphopenia and positive
ANA results. CTD defined diagnosis were: SLE, vasculi-
tis, Sjörgren’s Syndrome and Overlap Syndrome. In the
remaining 4 patients diagnosis was probable. In one
patient manifestations of CTD were simultaneous with
AIH diagnosis. In 3/8 patients manifestations were
before (25 months average) and in 4/8 were afterwards
(29 months average).
Conclusions
In 8 out of 20 patients AIH was associated with defined
or probable CTD. Three of the 8 patients developed
AIH after CTD diagnosis.
This association should be investigated in all patients
with AIH and CTD diagnosis.
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